台大急性腎損傷聯盟(NSARF)的簡介 (About NSARF)

台大急性腎損傷聯盟(NSARF)的簡介

    急性腎損傷（AKI）的發生率近年來明顯的增加。台灣的末期腎臟病（ESRD）發病率和患病率是世界上最高的。因此，慢性腎臟病（CKD）已成為國家公共衛生一個重要的課題。急性腎損傷會增加病患的死亡率，即使是血肌酐輕微的升高0.3毫克/分升或輕度蛋白尿，對病患的預後仍會產生不利影響。因此，急性腎損傷患者之後發生末期腎病的風險和長期的死亡率，皆比沒有急性腎損傷的患者來的高。我們建立的“台大急性腎損傷聯盟(NSARF)”，目標在於整合台灣腎臟疾病相關之研究資源，協助研究者進行尖端的多中心臨床試驗。

工作重點

 1.吸引國內外製藥與診療技術公司在台灣進行臨床試驗，促進國際研究合作，並提供成員參與國際臨床試驗的信息和機會。

 2.發展資源共享平台，進行共同研究並分享臨床試驗的相關數據和研究成果

台大急性腎臟損傷聯盟於近幾年成立,此聯盟由一群台灣大學之腎病學家於2004年建構。

此聯盟之第一項任務為建立正在接受腎臟替代療法之病患之前瞻性資料庫,為確保資料庫之品質與結果之完整,我們以進入加護病房之病患為收案目標,收受醫院為台大醫院及其分院,我們總共有6間加護病房,共76床,直到2014年,我們服務超過32000個病患,急性洗腎案例超過5000例。所有的臨床資料都會被登錄在制式表格上,並且定期由研究助理檢查,以確保數據品質。聯盟研究人員已經利用此資料庫進行許多研究。

現今,聯盟中的成員包含來自各地醫學中心或區域醫院之醫師、統計分析助理、行政人員、或實驗人員。 除了從NSARF資料庫研究， NSARF成員正努力於以全國人口為基礎的群組研究領域,並且使用台灣全民健康保險研究資料庫以評估急性腎臟疾病的長期關鍵影響，他們也渴望能有任何機會與其他優秀的研究團體在急性腎臟疾病領域進一步合作。

Brief introduction of NSARF   (National Taiwan University Hospital Study Group on Acute Renal Failure)(by Shiao CC)

National Taiwan University Hospital Study Group on Acute Renal Failure (NSARF) was initially built by a party of nephrologists in the National Taiwan University hospital in 2004.

 The first work of NSARF was to prospectively establish a database of patients undergoing renal replacement therapy. To assure data’s quality and outcome’s completeness, NSARF picked patients from the intensive care units (ICUs) in the tertiary hospital (National Taiwan University Hospital) and its branch hospitals in Taiwan. There are total 76 beds in 6 ICUs, serving more than 32,000 admissions and more than 5,000 acute dialysis sessions until 2014. All clinical information was recorded on a predetermined spreadsheet with regular check-ups by a research assistant to ensure data quality. Using the database, the NSARF investigators have conducted many studies with florid results.

Today, the NSARF consists of many physicians from different medical centers or regional hospitals, and many assistants for statistical analysis, administrative managers, or laboratory workers. Besides researches from the NSARF database, the members in NSARF is working hard in the field of nationwide population-based cohort studies using Taiwan National Health Insurance Research Database to evaluate the long-term pivotal effect of AKI, and they also hunger for any chance of further cooperation with other excellent study group in the field of AKI.

Aim of Work

Acute kidney injury (AKI) incidence increased significantly in recent years. Since the morbidity and prevalence of end-stage renal disease (ESRD) in Taiwan is the highest in the world, thus, chronic kidney disease (CKD) has become an important issue in national public health area. Acute kidney injury will increase patients’ mortalities; even a slight increase in serum creatinine 0.3 mg / dL or mild proteinuria, the prognosis of patients will still be adversely affected. Patients with acute kidney injury have higher risk to suffer from end-stage renal disease and long-term mortality than patients without acute kidney injury. For these reasons, we have established NSARF ( National Taiwan University Hospital study group on Acute Renal Failure), to integrate Taiwan's kidney disease-related research resources and to assist researchers conducted multi-center clinical trials.

Priorities

1.      Attract domestic and foreign pharmaceutical and medical technology companies to conduct clinical trials in Taiwan; promote international research cooperation, and provide information and opportunities for members to participate in international clinical trials.

2.      Develop the resource sharing platform for cooperation and sharing of relevant data and research results in clinical trials.